3 results match your criteria: "Jilin Provincial Hematology Research Institute[Affiliation]"
Nilotinib related acute myocardial infarction with nonobstructive coronary arteries: a case report and literature review.
BMC Cardiovasc Disord
February 2022
Department of Cardiology, China-Japan Union Hospital of Jilin University, Xiantai, Street No. 126, Changchun, 130033, Jilin Province, China.
Background: Myocardial Ischemia with No Obstructive Coronary Artery Disease (MINOCA) is a common cause of type 2 acute myocardial infarction (AMI) which requires careful differential diagnosis. Coronary artery spasm (CAS) syndrome is one etiology that can lead to MINOCA. Nilotinib, a targeted treatment for chronic myeloid leukemia (CML), has been reported to be related with increased risk of adverse vascular events.
View Article and Find Full Text PDFEffect of chidamide on treating hepatosplenic T-cell lymphoma: A case report.
World J Clin Cases
July 2020
Department of Hematology, The First Hospital of Jilin University, Jilin Provincial Hematology Research Institute, National Key Discipline, Changchun 130021, Jilin Province, China.
Background: Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of non-Hodgkin's lymphoma, which has an aggressive clinical course and an extremely poor prognosis. Chidamide is a novel, orally active, benzamide-type histone deacetylase (HDAC) inhibitor that has been used for peripheral T-cell lymphoma (PTCL) treatment. However, to date, there has been no report of the treatment and effect of the HDAC inhibitor chidamide in HSTCL, which is a special subtype of PTCL.
View Article and Find Full Text PDFD-dimer surge and coagulation disorders in COVID-19 related pneumonia patients with cardiac injury: A case series.
Medicine (Baltimore)
July 2020
Department of Hematology, The First Hospital of Jilin University, Jilin Provincial Hematology Research Institute, National Key Discipline.
Background: Cardiac injury and coagulation disorders have been two increasing concerns in the management of patients with severe coronavirus disease (COVID-19). Coagulation disorders in COVID-19 patients with cardiac injury have not been characterized.
Methods: We analyzed the data of five COVID-19 patients with cardiac injury who had D-dimer surge (defined as a rapid increase in the D-dimer level in 72 h, from <5-21 μg/mL) during hospitalization, which were extracted from a registered retrospective study (ChiCTR2000031301).